Philippines halts sale of Sanofi dengue vaccine

Philippines halts sale of Sanofi dengue vaccine

According to United Kingdom public broadcaster the BBC, Sanofi said in a press conference in Manila on Monday that there had been no reported deaths related to its dengue vaccine in the Philippines.

Last week, the Philippines' health department suspended the vaccination after Sanofi announced evidence showing that people who receive the vaccine, known as Dengvaxia, without previous dengue infection could face the risk of their disease worsening.

"Like many others in the Philippines, WHO is awaiting the expert analysis of new data and advice about its implications for use of the vaccine", the WHO said in a statement on its website. No cases in the most severe level were recorded, and all those stricken with dengue in the study have fully recovered, she said.

De Guzman said the PHO is "strengthening the campaign for the 4S program of the government" and urges the public to do so.

Philippine health officials have ordered Sanofi to jerk its dengue vaccine off the market as the controversy over the health threat it poses to children continues to roil the country.

In a report by the PHO in their "Dengue Surveillance" update (as of November 27, 2017) a total of 4,472 cases were reported, higher than the 3,824 cases reported past year.

Sanofi spent $1.8 billion over more than 20 years to prep this launch, expecting to develop a new franchise worth $1.5 billion a year.

The recent findings outline that sales forecasts may not be reached over the safety issues and clinical proofs that show unequal protection against various strains of dengue.

Health Secretary Francisco Duque III said the Philippines will wait for a recommendation to be released on December 12 or 13 by the Strategic Advisory Group of Experts on immunisation, an advisory body of the World Health Organization (WHO).

Mosquito nets are installed in a classroom at the Pantal Elementary School in Dagupan City to protect pupils from mosquitoes carrying the dengue virus, amid the controversy sparked by the suspension of the anti-dengue vaccination program due to health concerns.

The vaccine, given to anyone who had not already been infected, left people vulnerable to severe, life-threatening dengue in the event they were subsequently infected by wild type dengue.